ArticleDiscover oncology2025
Should follow-up cystoscopy be performed in upper-tract urothelial carcinoma patients managed with radical nephroureterectomy after a five-year bladder tumor-free period?
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
There is a lack of consensus regarding the follow-up schedule for patients with upper-tract urothelial carcinoma (UTUC) who remain bladder recurrence-free for 5 years after radical nephroureterectomy (RNU). In this study, we aimed to identify the risk factors for late recurrence in UTUC patients who remained bladder recurrence-free for at least 5 years post-RNU. Data from a large single-center Chinese institution were retrospectively analyzed. A total of 939 patients who remained recurrence-free for at least 5 years post-RNU were included in this study. To determine the risk factors for late bladder recurrence after RNU, we applied univariate and multivariate analyses using the Fine-Gray model, considering death as a competing risk. During a median follow-up of 97 months, 45 (4.8%) developed bladder recurrence, 207 (22%) died, and 61 (6.5%) succumbed to UTUC. The cumulative risk of bladder recurrence was 6.3% at 10 years and 13.9% at 15 years. The peak incidence of late bladder recurrence was observed between 70 and 90 months post-RNU. Univariate analysis revealed that Chronic Kidney Disease (CKD) stage 5 was significantly associated with late bladder recurrence.Multivariate analysis revealed that CKD stage 5 and tumor diameter less than 3 cm were independent risk factors for late bladder recurrence. These findings indicate that late bladder recurrence is uncommon and patients with CKD stage 5 or tumor diameter less than 3 cm are at a higher risk of late bladder recurrence, warranting prolonged cystoscopic surveillance for for 5 to 10 years post-RNU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.